Cetuximab (Cet), a monoclonal antibody targeting the epidermal growth factor (EGF) receptor (EGFR), is the first molecularly targeted drug approved for use in advanced head and neck squamous cell carcinoma (HNSCC). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.